DK2266582T3 - Farmaceutisk sammensætning til forebyggelse af dysbiose i forbindelse med enteral administration af antibiotika - Google Patents
Farmaceutisk sammensætning til forebyggelse af dysbiose i forbindelse med enteral administration af antibiotika Download PDFInfo
- Publication number
- DK2266582T3 DK2266582T3 DK08873434.8T DK08873434T DK2266582T3 DK 2266582 T3 DK2266582 T3 DK 2266582T3 DK 08873434 T DK08873434 T DK 08873434T DK 2266582 T3 DK2266582 T3 DK 2266582T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibiotic
- oligosaccharide
- pharmaceutical composition
- particle size
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Claims (8)
1. Farmaceutisk sammensætning til forebyggelse af tarmdysbiose under antibiotisk terapi, hvilken farmaceutisk sammensætning er beregnet til oral anvendelse og indeholder et antibiotikum og et præbiotikum, kendetegnet ved, at antibiotikummet og præbiotikummet er indbefattet i form af pulver, og den indbefatter, som præbiotikum, et oligosaccharid valgt fra gruppen omfattende fructooligosaccharider, galactooligosaccharider, xylooligosaccharider, maltooligosaccharider og isomaltooligosaccharider med polymeriseringsgrad fra 2 til 10, med partikelstørrelse på op til 0,3 mm og renhed på mindst 95%, og et antibiotikum med partikelstørrelse fra 20 til 200 ym, idet henholdsvis antibiotikummet og oligosaccharidet er indbefattet i en fast sammensætning i et vægtforhold på fra 1:1 til 1:100.
2. Farmaceutisk sammensætning ifølge krav 1, kendetegnet ved, at den indeholder en farmaceutisk acceptabel mængde af excipienser til forbedring af de organoleptiske egenskaber og forbrugeregenskaberne valgt fra gruppen omfattende fyldstoffer, smagskorrigerende stoffer, aromastoffer og duftstoffer.
3. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 og 2, kendetegnet ved, at den er fremstillet i en farmaceutisk form, som er egnet til oral anvendelse og er valgt fra gruppen omfattende kapsler, tabletter, pulvere, piller, sukkerovertrukne piller, granuler, breve, geler, pastaer, miksturer, emulsioner, suspensioner og opløsninger.
4. Farmaceutisk sammensætning til forebyggelse af tarmdysbiose under antibiotisk terapi, hvilken farmaceutisk sammensætning er beregnet til oral anvendelse og indeholder et antibiotikum og et præbiotikum, kendetegnet ved, at antibiotikummet og præbiotikummet er indbefattet i form af pulver, og endvidere at antibiotikummet, som er valgt fra gruppen omfattende beta-lactamer, der indbefatter kombination af beta-lactamer med hæmmere af bakterielle beta-lactamaser, azalider, fluorquinoloner, amphenicoler, glycopeptider, ansamyciner, nitrofuraner, derivater af phosphonsyre, cycloserin og trimetoprim, er indbefattet med partikelstørrelse fra 20 til 200 ym, og den indbefatter, som præbiotikum, et oligosaccharid med polymeriseringsgrad fra 2 til 10 og med en renhed på mindst 95%, idet antibiotikummet og oligosaccharidet er indbefattet i sammensætningen i et vægtforhold på fra 1:1 til 1:100.
5. Farmaceutisk sammensætning ifølge krav 4, kendetegnet ved, at den indeholder farmaceutisk acceptable mængder af excipienser til forbedring af de organoleptiske egenskaber og forbrugeregenskaberne valgt fra gruppen omfattende fyldstoffer, smagskorrigerende stoffer, aromastoffer og duftstoffer.
6. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 4 og 5, kendetegnet ved, at den er fremstillet i en farmaceutisk form, som er egnet til oral anvendelse og er valgt fra gruppen omfattende kapsler, tabletter, pulvere, piller, sukkerovertrukne piller, granuler, breve, geler, pastaer, miksturer, emulsioner, suspensioner og opløsninger.
7. Farmaceutisk sammensætning ifølge krav 1 til anvendelse til forebyggelse af tarmdysbiose under antibiotisk terapi ved oral administration.
8. Farmaceutisk sammensætning ifølge krav 4 til anvendelse til forebyggelse af tarmdysbiose under antibiotisk terapi ved oral administration.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2008/000151 WO2009116886A1 (ru) | 2008-03-18 | 2008-03-18 | Фармацевтическая композиция и способ профилактики дисбиозов, ассоциированных с энтеральным приемом антибиотиков |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2266582T3 true DK2266582T3 (da) | 2015-07-27 |
Family
ID=41091125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08873434.8T DK2266582T3 (da) | 2008-03-18 | 2008-03-18 | Farmaceutisk sammensætning til forebyggelse af dysbiose i forbindelse med enteral administration af antibiotika |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110200668A1 (da) |
| EP (1) | EP2266582B1 (da) |
| CN (1) | CN101998859B (da) |
| BR (1) | BRPI0822485A2 (da) |
| DK (1) | DK2266582T3 (da) |
| EA (1) | EA020023B1 (da) |
| ES (1) | ES2542879T3 (da) |
| HR (1) | HRP20150811T1 (da) |
| HU (1) | HUE025097T2 (da) |
| PL (1) | PL2266582T3 (da) |
| PT (1) | PT2266582E (da) |
| UA (1) | UA98215C2 (da) |
| WO (1) | WO2009116886A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201603856PA (en) | 2010-12-31 | 2016-07-28 | Abbott Lab | Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides |
| CN103379908B (zh) | 2010-12-31 | 2020-02-14 | 雅培制药有限公司 | 使用人乳寡糖、维生素c和抗炎剂减少氧化应激的发病率的方法 |
| CA2842672A1 (en) * | 2011-07-22 | 2013-01-31 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| CN104023560A (zh) | 2011-08-29 | 2014-09-03 | 雅培制药有限公司 | 用于预防胃肠道损伤和/或促进胃肠道愈合的人乳寡糖 |
| EP2790661B1 (de) | 2011-12-13 | 2018-06-27 | Henkel AG & Co. KGaA | Zusammensetzungen zur färbung keratinhaltiger fasern |
| GB201305708D0 (en) * | 2013-03-28 | 2013-05-15 | Clasado Inc | Novel use |
| CN108186661A (zh) * | 2017-12-15 | 2018-06-22 | 哈尔滨珍宝制药有限公司 | 一种包含盐酸克林霉素的药物组合物及其制备方法 |
| RU2675631C1 (ru) * | 2018-10-02 | 2018-12-21 | Общество с ограниченной ответственностью "Новые Биомедицинские Решения" | Местное гемостатическое средство с повышенной антимикробной активностью |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861172A (en) * | 1991-05-08 | 1999-01-19 | Laboratorios Beecham Sa | Pharmaceutical formulations of compacted granulates of β-lactam antibiotics |
| IT1271449B (it) * | 1993-04-28 | 1997-05-28 | Inalco Spa | Procedimento per la preparazione di lattulosio cristallino da sciroppi commerciali |
| US5827526A (en) * | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
| US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| DE60031385D1 (de) * | 2000-06-28 | 2006-11-30 | B S D Bio Science Dev Snc Di O | Pharmazeutische Zusammensetzungen von Antibiotika und Fruktan-Gemische |
| ATE361678T1 (de) * | 2000-12-27 | 2007-06-15 | Nutricia Nv | Ernährungszusammensetzung mit gesundheitsfördernder wirkung enthaltend oligosaccharide |
| CA2469246A1 (en) * | 2001-12-21 | 2003-07-03 | Pfizer Products Inc. | Directly compressible formulations of azithromycin |
| ITBO20020564A1 (it) * | 2002-09-06 | 2004-03-07 | Alfa Wassermann Spa | Bifidobatteri e preparazioni che li contengono. |
| RU2284832C2 (ru) | 2004-08-30 | 2006-10-10 | Николай Александрович Киселев | Антимикробная композиция для перорального введения |
-
2008
- 2008-03-18 DK DK08873434.8T patent/DK2266582T3/da active
- 2008-03-18 UA UAA201011851A patent/UA98215C2/ru unknown
- 2008-03-18 US US12/736,167 patent/US20110200668A1/en not_active Abandoned
- 2008-03-18 PT PT88734348T patent/PT2266582E/pt unknown
- 2008-03-18 CN CN200880128127.4A patent/CN101998859B/zh not_active Expired - Fee Related
- 2008-03-18 PL PL08873434T patent/PL2266582T3/pl unknown
- 2008-03-18 WO PCT/RU2008/000151 patent/WO2009116886A1/ru active Application Filing
- 2008-03-18 HU HUE08873434A patent/HUE025097T2/en unknown
- 2008-03-18 ES ES08873434.8T patent/ES2542879T3/es active Active
- 2008-03-18 EA EA201001099A patent/EA020023B1/ru not_active IP Right Cessation
- 2008-03-18 EP EP08873434.8A patent/EP2266582B1/en not_active Not-in-force
- 2008-03-18 BR BRPI0822485-4A patent/BRPI0822485A2/pt not_active Application Discontinuation
-
2015
- 2015-07-27 HR HRP20150811TT patent/HRP20150811T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101998859A (zh) | 2011-03-30 |
| EP2266582A1 (en) | 2010-12-29 |
| HRP20150811T1 (hr) | 2015-09-11 |
| WO2009116886A1 (ru) | 2009-09-24 |
| HUE025097T2 (en) | 2016-01-28 |
| BRPI0822485A2 (pt) | 2015-06-16 |
| PT2266582E (pt) | 2015-09-04 |
| EA201001099A1 (ru) | 2011-02-28 |
| CN101998859B (zh) | 2014-03-05 |
| PL2266582T3 (pl) | 2015-10-30 |
| US20110200668A1 (en) | 2011-08-18 |
| ES2542879T3 (es) | 2015-08-12 |
| EP2266582B1 (en) | 2015-04-29 |
| EA020023B1 (ru) | 2014-08-29 |
| EP2266582A4 (en) | 2011-03-02 |
| UA98215C2 (ru) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2266582T3 (da) | Farmaceutisk sammensætning til forebyggelse af dysbiose i forbindelse med enteral administration af antibiotika | |
| US6706287B2 (en) | Prebiotic and probiotic compositions and methods for their use in gut-based therapies | |
| PL199180B1 (pl) | Zastosowanie fizjologicznie dopuszczalnych mieszanin enzymów | |
| Tester et al. | Intrinsic and extrinsic carbohydrates in the vagina: a short review on vaginal glycogen | |
| ES2545105T3 (es) | Composición farmacéutica a base de un agente protector hepático y de un agente prebiótico, su preparación y uso | |
| CN106820151A (zh) | 一种双壳复合保健组合物、制备方法及应用 | |
| CA2132427A1 (en) | Method and composition for suppresion of side effects of anti-inflammatory drugs | |
| JP4808619B2 (ja) | 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁 | |
| CN109620948A (zh) | 高尿酸/痛风的全自然细胞调理方法 | |
| US7026160B2 (en) | Oral bacteriotherapy compositions and methods | |
| CN107158225A (zh) | 一种生脉饮组合物及其制备方法和应用 | |
| RU2325187C1 (ru) | Фармацевтическая композиция антибиотиков и пребиотиков (варианты) для профилактики и лечения дисбиозов в процессе антибактериальной терапии | |
| RU2325166C1 (ru) | Фармацевтическая композиция антибиотиков и лактулозы для профилактики энтеральных дисбиозов в процессе антибиотикотерапии | |
| DK2266581T3 (da) | Farmaceutisk sammensætning af antibiotika og præbiotika til forebyggelse og behandling af dysbiose under antibakteriel terapi | |
| US20210236537A1 (en) | High porosity cellulosic structures and methods of treatment therewith | |
| JP3884611B2 (ja) | 衝動性疾患の改善剤 | |
| EP1157697A1 (en) | Remedies for hyperammonemia | |
| US20200197448A1 (en) | Application of Alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases | |
| US6488969B1 (en) | Method for reducing blood ammonia concentration | |
| RU2755707C1 (ru) | Средство для коррекции диспептических расстройств желудочно-кишечного тракта | |
| JPH0131487B2 (da) | ||
| RU2692243C1 (ru) | Применение лактитола и пероральная лекарственная форма для лечения и профилактики неалкогольной жировой болезни печени | |
| KR101956528B1 (ko) | 저알부민혈증 개선용 조성물 | |
| TW201012474A (en) | Treatment of fructose malabsorption | |
| EP4308138A1 (fr) | Inhibiteurs glycosidiques de levure |